Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Does early antipsychotic response predict long-term treatment outcome?

Rasmussen SA, Rosebush PI, Mazurek MF.

Hum Psychopharmacol. 2017 Nov;32(6). doi: 10.1002/hup.2633. Epub 2017 Sep 26.

PMID:
28952166
2.

Mental illness in patients with inherited mitochondrial disorders.

Rosebush PI, Anglin RE, Rasmussen S, Mazurek MF.

Schizophr Res. 2017 Sep;187:33-37. doi: 10.1016/j.schres.2017.05.010. Epub 2017 May 23. Review. No abstract available.

PMID:
28545943
3.

Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology.

Rasmussen SA, Mazurek MF, Rosebush PI.

World J Psychiatry. 2016 Dec 22;6(4):391-398. doi: 10.5498/wjp.v6.i4.391. eCollection 2016 Dec 22. Review.

4.

The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects.

Rasmussen SA, Rosebush PI, Mazurek MF.

J Clin Psychopharmacol. 2017 Feb;37(1):8-12. doi: 10.1097/JCP.0000000000000637.

PMID:
28027109
5.

The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.

Rasmussen SA, Rosebush PI, Anglin RE, Mazurek MF.

Psychiatry Res. 2016 Jul 30;241:72-7. doi: 10.1016/j.psychres.2016.04.097. Epub 2016 Apr 29.

PMID:
27156027
6.

Cushing Disease Presenting as Primary Psychiatric Illness: A Case Report and Literature Review.

Rasmussen SA, Rosebush PI, Smyth HS, Mazurek MF.

J Psychiatr Pract. 2015 Nov;21(6):449-57. doi: 10.1097/PRA.0000000000000113.

PMID:
26554329
7.

Metabolite measurements in the caudate nucleus, anterior cingulate cortex and hippocampus among patients with mitochondrial disorders: a case-control study using proton magnetic resonance spectroscopy.

Anglin RE, Rosebush PI, Noseworthy MD, Tarnopolsky M, Weber AM, Soreni N, Mazurek MF.

CMAJ Open. 2013 Apr 26;1(1):E48-55. doi: 10.9778/cmajo.20120020. eCollection 2013 Jan.

8.

The psychiatric presentation of mitochondrial disorders in adults.

Anglin RE, Tarnopolsky MA, Mazurek MF, Rosebush PI.

J Neuropsychiatry Clin Neurosci. 2012 Fall;24(4):394-409. doi: 10.1176/appi.neuropsych.11110345. Review.

PMID:
23224446
9.

Psychiatric symptoms correlate with metabolic indices in the hippocampus and cingulate in patients with mitochondrial disorders.

Anglin RE, Rosebush PI, Noseworthy MD, Tarnopolsky M, Mazurek MF.

Transl Psychiatry. 2012 Nov 13;2:e187. doi: 10.1038/tp.2012.107.

10.

The mitochondrial genome and psychiatric illness.

Anglin RE, Mazurek MF, Tarnopolsky MA, Rosebush PI.

Am J Med Genet B Neuropsychiatr Genet. 2012 Oct;159B(7):749-59. doi: 10.1002/ajmg.b.32086. Epub 2012 Aug 6. Review.

PMID:
22887963
11.

The psychiatric manifestations of mitochondrial disorders: a case and review of the literature.

Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, Rosebush PI.

J Clin Psychiatry. 2012 Apr;73(4):506-12. doi: 10.4088/JCP.11r07237. Review.

PMID:
22579150
12.

The comparative effects of environmental enrichment with exercise and serotonin transporter blockade on serotonergic neurons in the dorsal raphe nucleus.

MacGillivray L, Reynolds KB, Rosebush PI, Mazurek MF.

Synapse. 2012 May;66(5):465-70. doi: 10.1002/syn.21511. Epub 2012 Jan 4.

PMID:
22121041
13.

Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra.

MacGillivray L, Reynolds KB, Sickand M, Rosebush PI, Mazurek MF.

Synapse. 2011 Nov;65(11):1166-72. doi: 10.1002/syn.20954. Epub 2011 Jun 10.

PMID:
21584867
14.

Treatment of conversion disorder in the 21st century: have we moved beyond the couch?

Rosebush PI, Mazurek MF.

Curr Treat Options Neurol. 2011 Jun;13(3):255-66. doi: 10.1007/s11940-011-0124-y.

PMID:
21468672
15.

Role of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neurons.

Reynolds KB, MacGillivray L, Zettler M, Rosebush PI, Mazurek MF.

Brain Res. 2011 Jun 7;1394:24-32. doi: 10.1016/j.brainres.2011.03.003. Epub 2011 Mar 8.

PMID:
21396352
16.

Resolution of catamenial epilepsy after goserelin therapy and oophorectomy: case report of presumed cerebral endometriosis.

Vilos GA, Hollett-Caines J, Abu-Rafea B, Ahmad R, Mazurek MF.

J Minim Invasive Gynecol. 2011 Jan-Feb;18(1):128-30. doi: 10.1016/j.jmig.2010.09.002.

PMID:
21195968
17.

Role of serotonin transporter inhibition in the regulation of tryptophan hydroxylase in brainstem raphe nuclei: time course and regional specificity.

MacGillivray L, Lagrou LM, Reynolds KB, Rosebush PI, Mazurek MF.

Neuroscience. 2010 Dec 1;171(2):407-20. doi: 10.1016/j.neuroscience.2010.08.055. Epub 2010 Sep 22.

PMID:
20868730
18.

Neuroleptic malignant syndrome: a neuroimmunologic hypothesis.

Anglin RE, Rosebush PI, Mazurek MF.

CMAJ. 2010 Dec 14;182(18):E834-8. doi: 10.1503/cmaj.091442. Epub 2010 Aug 9. Review. No abstract available.

19.

Treating psychiatric illness in patients with mitochondrial disorders.

Anglin RE, Rosebush PI, Mazurek MF.

Psychosomatics. 2010 Mar-Apr;51(2):179; author reply 179-80. doi: 10.1176/appi.psy.51.2.179. No abstract available.

PMID:
20332296
20.

Catatonia and its treatment.

Rosebush PI, Mazurek MF.

Schizophr Bull. 2010 Mar;36(2):239-42. doi: 10.1093/schbul/sbp141. Epub 2009 Dec 7. Review.

21.

Role of AP-2alpha transcription factor in the regulation of synapsin II gene expression by dopamine D1 and D2 receptors.

Skoblenick KJ, Argintaru N, Xu Y, Dyck BA, Basu D, Tan ML, Mazurek MF, Mishra RK.

J Mol Neurosci. 2010 Jun;41(2):267-77. doi: 10.1007/s12031-009-9299-z. Epub 2009 Oct 20.

PMID:
19842069
22.

Neuroleptic malignant syndrome and the acute phase response.

Rosebush PI, Anglin RE, Richards C, Mazurek MF.

J Clin Psychopharmacol. 2008 Aug;28(4):459-61. doi: 10.1097/JCP.0b013e31817ea9c1. No abstract available.

PMID:
18626278
23.

The neuropsychiatric profile of Addison's disease: revisiting a forgotten phenomenon.

Anglin RE, Rosebush PI, Mazurek MF.

J Neuropsychiatry Clin Neurosci. 2006 Fall;18(4):450-9. Review.

PMID:
17135373
24.

Recognizing neuroleptic malignant syndrome.

Rosebush PI, Garside S, Mazurek MF.

CMAJ. 2004 May 25;170(11):1645. No abstract available.

25.

Magnetic resonance imaging abnormalities and psychiatric illness.

Garside S, Rosebush PI, Levinson AJ, Mazurek MF.

Am J Psychiatry. 2000 Feb;157(2):306-7. No abstract available.

PMID:
10671427
26.

Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms.

Garside S, Rosebush PI, Levinson AJ, Mazurek MF.

J Clin Psychiatry. 1999 Jul;60(7):460-8. Review.

PMID:
10453801
27.

The neuropsychiatry of adult-onset adrenoleukodystrophy.

Rosebush PI, Garside S, Levinson AJ, Mazurek MF.

J Neuropsychiatry Clin Neurosci. 1999 Summer;11(3):315-27. Review.

PMID:
10440007
28.

Serotonin syndrome as a result of clomipramine monotherapy.

Rosebush PI, Margetts P, Mazurek MF.

J Clin Psychopharmacol. 1999 Jun;19(3):285-7. No abstract available.

PMID:
10350043
29.

Catatonia: re-awakening to a forgotten disorder.

Rosebush PI, Mazurek MF.

Mov Disord. 1999 May;14(3):395-7. No abstract available.

PMID:
10348460
30.

Catatonia following gabapentin withdrawal.

Rosebush PI, MacQueen GM, Mazurek MF.

J Clin Psychopharmacol. 1999 Apr;19(2):188-9. No abstract available.

PMID:
10211925
31.

Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone.

Rosebush PI, Mazurek MF.

Neurology. 1999 Mar 10;52(4):782-5.

PMID:
10078728
32.

Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal.

Mazurek MF, Savedia SM, Bobba RS, Garside S, Rosebush PI.

J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):799-801.

33.

Neuropsychiatric aspects of the adult variant of Tay-Sachs disease.

MacQueen GM, Rosebush PI, Mazurek MF.

J Neuropsychiatry Clin Neurosci. 1998 Winter;10(1):10-9. Review.

PMID:
9547461
34.
36.

The ontogeny of NADPH-diaphorase neurons in serum-free striatal cultures parallels in vivo development.

Garside S, Woulfe J, Mazurek MF.

Neuroscience. 1997 May;78(2):615-24.

PMID:
9145814
37.

Cortical peptide changes in Huntington's disease may be independent of striatal degeneration.

Mazurek MF, Garside S, Beal MF.

Ann Neurol. 1997 Apr;41(4):540-7.

PMID:
9124812
38.

Protracted akathisia after risperidone withdrawal.

Rosebush PI, Kennedy K, Dalton B, Mazurek MF.

Am J Psychiatry. 1997 Mar;154(3):437-8. No abstract available.

PMID:
9054802
39.

The ontogeny of NADPH-diaphorase neurons in serum-free striatal cultures parallels in vivo development.

Garside S, Woulfe J, Mazurek MF.

Neuroscience. 1997 Feb;76(4):1221-30. Corrected and republished in: Neuroscience. 1997 May;78(2):615-24.

PMID:
9027880
40.
41.

Catatonia after benzodiazepine withdrawal.

Rosebush PI, Mazurek MF.

J Clin Psychopharmacol. 1996 Aug;16(4):315-9.

PMID:
8835707
42.

Circadian pattern of acute, neuroleptic-induced dystonic reactions.

Mazurek MF, Rosebush PI.

Am J Psychiatry. 1996 May;153(5):708-10.

PMID:
8615420
43.
44.

Complicating factors in the analysis of acute drug-induced akathisia.

Rosebush PI, Mazurek MF.

Arch Gen Psychiatry. 1995 Oct;52(10):878-80. No abstract available.

PMID:
7575110
45.

Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues.

Rosebush PI, MacQueen GM, Clarke JT, Callahan JW, Strasberg PM, Mazurek MF.

J Clin Psychiatry. 1995 Aug;56(8):347-53. Review.

PMID:
7635850
46.

Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers.

Gaind GS, Rosebush PI, Mazurek MF.

J Clin Psychiatry. 1994 Jan;55(1):20-3.

PMID:
8294387
47.

Reduced cerebral cortical but elevated striatal concentration of somatostatin-like immunoreactivity in dominantly inherited olivopontocerebellar atrophy.

Kish SJ, Robitaille Y, el-Awar M, Schut L, DiStefano L, Ball MJ, Mazurek MF.

J Neurol Neurosurg Psychiatry. 1993 Sep;56(9):1013-5.

48.

Do benzodiazepines modify the incidence of neuroleptic-induced dystonia?

Rosebush PI, Mazurek MF.

Am J Psychiatry. 1993 Mar;150(3):528-9. No abstract available. Erratum in: Am J Psychiatry 1993 Nov;150(11):1762.

PMID:
8094602
50.

The treatment of catatonia: benzodiazepines of ECT?

Rosebush PI, Hildebrand AM, Mazurek MF.

Am J Psychiatry. 1992 Sep;149(9):1279-80. No abstract available.

PMID:
1503150

Supplemental Content

Loading ...
Support Center